retatrutide sell | 2381089-83-2 | FR04570 Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

Patients should never adjust doses without consulting their healthcare provider

For full manual prior authorization or medical necessity criteria for GLP-1 medications, please use the TRICARE Formulary Search Tool

Symptom-Triggered Testing Persistent severe abdominal pain: urgent evaluation, lipase testing, and appropriate imaging Right-upper-abdominal pain or jaundice: liver and biliary testing plus gallbladder imaging Persistent vomiting or diarrhea: kidney function and electrolyte testing Symptoms of hypoglycemia: immediate glucose evaluation Fatigue or signs of deficiency: CBC and selected nutritional tests Testing should not delay medical care for severe symptoms

7 Beyond weight loss Semaglutide has gained significant attention for its positive effects in managing type 2 diabetes (T2D), obesity, and cardiovascular risk reduction